MiMedx Group (MiMedx Group) Debt-to-Equity

: 0.34 (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

MiMedx Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.0 Mil. MiMedx Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $48.1 Mil. MiMedx Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $142.7 Mil. MiMedx Group's debt to equity for the quarter that ended in Dec. 2023 was 0.34.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MiMedx Group's Debt-to-Equity or its related term are showing as below:

MDXG' s Debt-to-Equity Range Over the Past 10 Years
Min: -317.98 Med: 0.34 Max: 586.92
Current: 0.34

During the past 13 years, the highest Debt-to-Equity Ratio of MiMedx Group was 586.92. The lowest was -317.98. And the median was 0.34.

MDXG's Debt-to-Equity is ranked worse than
68.03% of 1073 companies
in the Biotechnology industry
Industry Median: 0.14 vs MDXG: 0.34

MiMedx Group Debt-to-Equity Historical Data

The historical data trend for MiMedx Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

1.91

-317.98

586.92

-2.70

0.34

MiMedx Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																-2.70	-2.71	-3.86	36.82	0.34

Competitive Comparison

For the Biotechnology subindustry, MiMedx Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiMedx Group Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, MiMedx Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MiMedx Group's Debt-to-Equity falls into.

MiMedx Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MiMedx Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	48.099)	/	142.717
	=	0.34

MiMedx Group's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	48.099)	/	142.717
	=	0.34

MiMedx Group (NAS:MDXG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

MiMedx Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of MiMedx Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

MiMedx Group (MiMedx Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062

Website

https://www.mimedx.com

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Executives

Rice Doug	officer: Chief Financial Officer	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper	officer: Chief Executive Officer	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein	officer: EVP, Research and Development	C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson	officer: Chief Financial Officer	BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan	officer: Chief Accounting Officer	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Hulse William Frank Iv	officer: General Counsel	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow	officer: Chief Operating Officer	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rohit Kashyap	officer: EVP & Chief Commercial Officer	8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright	director, officer: Chief Executive Officer	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves	officer: SVP & Chief Compliance Officer	1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner	officer: SVP, Operations & Procurement	1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner	director	618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani	director	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin	director	C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins	director	MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604